2. Search Result
Search Result
Results for "

electroshock

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133486
    GABAA receptor agent 1

    		GABA Receptor Neurological Disease
    GABAA receptor agent 1 is a high affinity ligand for GABAA receptor, with potent anticonvulsant activity .
    GABAA receptor agent 1
  • HY-123671
    CYM2503

    		Neuropeptide Y Receptor Neurological Disease
    CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .
    CYM2503
  • HY-W322222
    Ethyl (E,Z)-2,4-decadienoate

    		Others Endocrinology
    Ethyl (E,Z)-2,4-decadienoate is a pheromone that induces an electroshock response in male cold moths (Sensilla Auricillica) and can be isolated from host plants .
    Ethyl (E,Z)-2,4-decadienoate
  • HY-106424
    Soretolide

    		Others Neurological Disease
    Soretolide is an antiepileptic agent. Soretolide is effective in maximal electroshock-induced seizure (MES) test in rodents. Soretolide inhibits metabolism of Phenytoin (HY-B0448). Soretolide exhibits a good pharmacokinetic character in rats model .
    Soretolide
  • HY-N12840
    Logmalicid B

    		Others Metabolic Disease
    Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .
    Logmalicid B
  • HY-100377
    Lvguidingan

    Anticonvulsant 7903

    		 Others Neurological Disease
    Lvguidingan is a potent anticonvulsant agent. Lvguidingan also has sedative-hypnotic, tranquilizing, and muscle-relaxing actions. Lvguidingan can be used as antiepileptic agent .
    Lvguidingan
  • HY-148135
    hCAI/II-IN-6

    		Carbonic Anhydrase Neurological Disease
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
    hCAI/II-IN-6
  • HY-B1730
    Phensuximide
    1 Publications Verification

    		 Others Neurological Disease Metabolic Disease
    Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
    Phensuximide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: